We have placed cookies on your computer to help make this website better. We use a Matomo Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by Matomo (e.g. deny use/opt-out).

I'm ok with this

Public Private Partnerships | Partnering | Grünenthal Group

Partnerships and collaborations

Public-Private Partnerships

We work with the world’s biggest public-private partnership organisation in the life sciences as co-leaders of the latest pain initiative.

The Pain Group of the Innovative Medicines Initiative 2 (IMI2) unites European pharmaceutical companies dedicated to better understanding, treating and managing pain. The framework of the public-private partnership enables a portfolio of pain projects addressing a broad spectrum of relevant challenges together with the best skilled public consortia of expert academics, hospitals, small and medium-sized enterprises (SMEs) and patient groups.

The IMI is a public-private partnership between the EU and EFPIA (European Federation of Pharmaceutical Industries and Associations) companies and is working to improve health by speeding up the development of and access to the next generation of medicines, particularly in areas of unmet medical and social need.


Deciphering pain – paving the way for safe, effective Treatments
The first collaborative project with the IMI2 started in April 2017, with the aim of generating predictive research approaches to guide the discovery of disease-modifying analgesics. Over the course of 3 years, the Modelling Neuron-Glia Networks into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) project will investigate neuron-glia interactions by developing authentic cellular (co-culture) assays using neuronal and glial cell types derived from human induced pluripotent stem cells (iPSC). This project will increase our knowledge of pain targets and pathways, and generate predictive approaches for the discovery of new pain treatments.


IMI-PainCare – Improving the care of patients suffering from acute or chronic pain

To improve the care of patients with acute or chronic pain, a consortium of academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project “IMI-PainCare – Improving the care of patients suffering from acute or chronic pain” on April 01, 2018.

We are proud to co-lead this important project together with Rolf-Detlef Treede from the University of Heidelberg. IMI-PainCare comprises three sub-projects PROMPT, BioPain and TRiPP, across all phases of the pharmaceutical value chain – from early research to clinical practice – addressing major challenges in the care of patients suffering from acute or chronic pain in a complementary manner. It is anticipated that tools will be validated that will allow patient stratification and enrichment as recommended by the recent EMA/CHMP/970057/2011 guideline on pain treatment.

More information: https://www.imi-paincare.eu/


PARADIGM – Patients Active in Research and Dialogues for an Improved Generation of Medicines

We are contributing to PARADIGM, a public-private partnership co-lead by the European Patients’ Forum and EFPIA that aims to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players.

To achieve this mission, processes and tools for three key decision-making points – research priority setting, design of clinical trials and early dialogue – need to be developed integrating the needs, perspectives and expectations of all actors (including vulnerable populations) involved.

More information: imi-paradigm.eu/


Creating a network of partnerships – future developments

We will join two other IMI2 projects to establish networks of specialists starting in 2018: the “European Screening Center Unprecedented Leverage of Attractive Biology“ (ESCulab) and “Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice” (DIAMOND).

External Link:
You are now leaving the Grünenthal (IE) website. You will be re-directed to an external website. Grünenthal Pharma Ltd., Ireland accepts no responsibility for the content of other websites. ... Cancel ... Ok